"preclinical antibody Development for prevention of AMR bacteria

I hypothesise that mAbs can protect against Gram negative bacterial infections in the lung. In order to test this hypothesis I will first develop mouse models of bacterial lung infection. Once those models have been established I will use them to test the efficacy of the first generation human mAb from Kymab, the industrial partner for my CASE studentship. This antibody targets poly-N-acetylglucosamine, a capsular bacterial polysaccharide that is highly conserved (Skurnik et al., 2016). In theory, this mAb should be broadly acting across a range of Gram negative bacteria. After testing the first generation mAbs in vivo I will go to Kymab to generate second generation mAbs. I will then test the efficacy of these second generation mAbs in comparison to the first generation mAbs.